BN Business News
Add your company to Business Communicator →

Business · 16/11/20261 min read

Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

- ASC30_48 FDC, a first-in-class once-daily oral dual fixed-dose combination targeting GLP-1R and GIPR, achieved approximately 52% relative improvement in weight loss compared to ASC30 alone - ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist designed for once-monthly to once-quarterly...

Original source language: PR Newswire — Global News ReleasesOpen original release →

Explore insights

Business insights →